Compared to Standard of Care: Phase 3 MajesTEC-3 study reveals TECVAYLI® plus DARZALEX FASPRO® combination significantly improves PFS and overall survival (https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-majestec-3-tecvayli-darzalex-results)

Source URL: https://www.myeloma.org/news-events/multiple-myeloma-news/phase-3-majestec-3-tecvayli-darzalex-results